Background: The underlying mechanism of allergen-specific subcutaneous
adaptive immune response in allergic asthma. It is clear that the innate immune response functions beyond sparking off allergic airway inflammation but that it is also involved in the chronic character of the inflammation. Asthma patients have an increased expression of the innate cytokines IL-33, TSLP and IL-25 in their lungs. [4] [5] [6] In severe asthmatics, ILC2s were even the most predominant source of IL-5 and IL-13 despite CD4 + T cells were more abundant. 8, 9 From mouse studies, it has been demonstrated that ILC2s are able to induce an eosinophilic airway inflammation and airway hyper-reactivity even in the absence of T cells. 10 Together with the observation that genetic variability in IL-33 and the IL-33 receptor is associated with asthma, these findings emphasize the role of IL-33 and ILC2s in the asthmatic airway inflammation. 11 This innate lymphoid cell type functions beyond the induction of the primary inflammatory response to the allergen and fulfils a prominent role in the maintenance of chronic asthma. The relative contribution of Th2 cells vs ILC2s is still under debate. 7, 12 The epithelium secretes innate inflammatory cytokines, like IL-33, IL-25, TSLP and GM-CSF, after an encounter with allergens but possibly also after nonallergenic stimuli (eg cold air). 13 Epithelium can respond to allergens by recognizing evolutionarily conserved patterns or it becomes activated by allergens exerting protease activity, like some major house dust mite allergens or pollen allergens. 14, 15 The secreted innate cytokines IL-33, IL-25, TSLP and GM-CSF are pluripotent and effect many innate and adaptive immune cells that contribute to the Th2 response.
Epithelial cells can promote a Th2 response by upregulating OX40L
on DCs and can activate innate lymphoid cells type 2 (ILC2s). 16 Recently, it has been demonstrated that ILC2s have a crucial role in the leakiness of the asthmatic epithelium by disrupting epithelial tight junctions by IL-13. 15 This could facilitate an increased entry of allergens. Oliphant et al demonstrated an allergen-specific feedback mechanism in which Th2 cells can interact with ILC2s via MHCII and activate ILC2s via secreted IL-2. A decrease in allergen-specific Th2 cells can therefore result in dampening the ILC2 population and activation. 17 Lao-Araya et al 18 showed that patients treated with a subcutaneous grass pollen-specific immunotherapy did not show the seasonal increase in ILC2s in PBMCs as seen in untreated patients, indicating that SCIT can suppress circulating ILC2s.
Besides the contribution of inflammation to the pathology of asthma, structural changes in the airways are equally important. 19 Asthma patients often show a thickened reticular basement membrane and an increased volume of airway smooth muscle. Interestingly, it was shown that fibroblasts from asthmatic biopsies were able to produce collagen after stimulation with IL-33. 20 In a mouse model for chronic asthma with airway remodelling and persistent airway hyper-reactivity, it was demonstrated that elimination of T cells resolved airway inflammation but not remodelling. Elimination of T cells and ILC2s resulted in resolution of airway hyper-reactivity. 7 Together, these data underline the involvement of the innate immune response in asthma.
In this study, we investigated in a mouse model whether suppression of the adaptive immune response by birch pollen-specific SCIT treatment is sufficient to decrease the number of airway ILC2s, innate cytokine production and prevent collagen deposition in the airways. 21 
| MATERIALS AND METHODS

| Mice
Female 6-8-week-old BALB/c mice (Envigo, Horst, the Netherlands)
were housed under specific pathogen-free conditions at the animal facility of the AMC. All experiments were approved by the Animal 
| Ex-vivo restimulation of lung-draining lymph node cells
Lung draining lymph node cell suspensions were plated in 96-well round-bottom plates at a density of 2 × 10 5 cells per well and were restimulated for 4 days with 100 μg/mL BPE. Supernatants were analysed for IL-2, 4, -5, -13, -10, -17A and IFNγ production by ELISA (Ready-set-go!, eBioscience). eBioscience) as previously described. 21 In short, Maxisorp plates were coated overnight with 100 μg BPE. After blocking with 10% FCS, serum samples were incubated for 2 hours and followed by an HRP detection step, according to the manufacturer's instructions. 
| Serum BP-specific Immunoglobulins
| Airway histology
Frozen sections (6 μm) were stained with Periodic Acid Schiff's reagent (Sigma-Aldrich). Degree of inflammation and mucus production was semi-quantified as described before. 23 The collagen deposition was determined on frozen sections stained with Martius Scarlet
Blue staining and was quantified via image analysis as described before. 23 In short, threshold Red Green Blue (RGB) values were specified for collagen staining, and the area collagen deposition per μm basement membrane was determined using an image analysing system (LEICA, Wetzlar, Germany). The determined area of pixels within the selected colour setting was divided by the length of BM of each airway, from each animal ten airways were analysed.
| Cytokine detection in lung tissue
Lungs were harvested and lung homogenate was lysed by adding
aprotinin (all 20 ng/mL), pH 7.4) after 30 minutes incubating on ice.
Then, the lysate was centrifuged at 500×g for 10 minutes and the supernatant was stored at −20°C until further use. The concentration (mg/mL) of total lung protein was measured by using BCA Protein Assay Kit according to manufacturer's instruction (PierceThermo Fisher Scientific, Rockford, USA). IL-33, IL-25, TSLP and GM-CSF protein concentration (μg/mg total protein) was measured by ELISA (Ready-SET-Go ELISA KIT, eBioscience).
For IL-5 production by lung ILC2s, lung tissue was minced in small fragments and digested with collagenase IV (100 U/mL) for 60 minutes at 37°C. Red blood cells were lysed with Ammonium chloride lysis buffer. Cells were stained for surface markers to identify ILC2 and stained for intracellular IL-5 as described above for BALF ILC2s ( Figure S1 ).
| Tryptase activity
Tryptase activity was determined in BALF as described before. 24 In short, 10 μL 6-mmol/L chromogenic tryptase substrate S-2288 (Chromogenix Instrumentation Laboratory, Milan, Italy) was added to 70 μL 57 mmol/L Tris-HCl (pH 8.3) in a 96-well microtiter plate.
Undiluted BALF sample (40 μL) was added to start the reaction. The use of the substrate was followed for one hour at 450 nm at 37°C.
The difference in optical density (OD) at each time point was calculated compared to the OD at the zero time point.
| Statistical analysis
For statistical analysis, differences between groups were analysed with the Mann-Whitney U test. Association between parameters was determined by Pearson Correlation Coefficient r. Differences were considered to be significant at a P value of less than 0.05.
| RESULTS
| BP SCIT does not inhibit the increased IL-33, IL-25 and GM-CSF production in lung
We demonstrated before that in mice with BP induced asthma, the adaptive immune response to BP can be suppressed by treatment with subcutaneous immunotherapy with a high dose of BP. In the present study, we explored the effect on the innate immune response to BP. First, we confirmed that BP SCIT treatment strongly decreased the Th2 cytokine production and the related eosinophilia, and that the BP-specific immunoglobulin response shifted from IgE towards an IgG 1 /G 2a response ( Figure 1A -D and Figure S2 ). 21 To investigate whether BP SCIT would also have an effect on the nonallergen-specific innate response after BP aerosol exposure of BP sensitized mice, we determined the level of the innate cytokines IL- 
| BP SCIT reduces the number of ILC2s
As IL-33 and IL-25 are important activators of ILC2s, [25] [26] [27] 
| BP SCIT does not reduce collagen deposition or mucus production
BP SCIT is able to reduce the adaptive immune response, the accumulation of ILC2s and the degranulation of mast cells. As both ILC2s and mast cells have been thought to be involved in remodelling of the airways, we analysed mucus production and collagen deposition after BP SCIT. BP sensitization and challenge induced mucus production and collagen deposition in the lungs of mice. BP SCIT was able to inhibit the inflammatory infiltrate and the mucus production (Figure 5A ), but the residual mucus production was still substantial and did not return to baseline ( Figure 5A,C) . On the other hand, BP SCIT did not reduce the degree of collagen deposition. BP sensitized/challenged mice and BP SCIT treated mice had a similar collagen deposition ( Figure 5D and quantified in B).
| DISCUSSION
Here, we show that BP allergen-specific immunotherapy not only suppressed the adaptive immune response to inhaled BPE but also ILC2s are recruited from the bone marrow, via the blood to the lungs. Also, the above described human study showed a reduction in circulating ILC2s in blood after grass pollen SCIT. 18 In support, Christianson showed that after irradiation of mice with a chronic airway inflammation, the number of depleted ILC2s was quickly restored by a transfer with naïve donor bone marrow. Importantly, they also observed that the number of restored (donor derived) ILC2s was higher in mice which had a chronic airway inflammation before they were irradiated compared with irradiated PBS control mice. This was suggested to be dependent on the persistent IL-33 expression in the lung. 34 Fourthly, an allergen-specific feedback mechanism has been described via MHCII expression by ILC2s which can interact with allergen-specific Th2 cells. 17 This could regulate the ILC2 population in an allergen-specific manner. In pilot experiments, we have analysed MHCII expression, but in our hands MHCII expression on BALF and lung ILC2s did not exceed control staining, making this explanation unlikely.
In addition, eosinophils can contribute to the proliferation and IL-5/IL-13 cytokine production by ILC2s. An important chemoattractant for eosinophils is eotaxin-2, which is under the control of Th2 cytokine IL-13. 35 Both the concentration of eotaxin-2 and IL-13 were significantly decreased in the BALF after BP SCIT. A suppression of BP-specific Th2 cells in the IL-13 production can limit the IL-5 + ILC2
population via this feedback system. In support of these proposed interactions, the decrease in T cells and eosinophils was accompanied by a decrease in ILC2s.
As IL-33 is involved in the degranulation of mast cells, 36 we determined both MMCP-1 in serum and tryptase activity in BALF.
Both were significantly decreased in mice treated with BP SCIT.
These are markers for degranulation, but further research is needed to determine whether the number of mast cells is reduced or whether degranulation of mast cells is truly inhibited. In the most recent international consensus about allergen-specific immunotherapy, it was stated that effective therapy should control chronic events leading to remodelling. Although allergen-specific immunotherapy is often used as a treatment for allergic asthma, there is still a matter of debate whether it is effective. Most controlled clinical trials were not designed specifically for asthma.
However, both the inflammation-dependent as the independent pathways involved in remodelling will need further elucidation to design an effective therapy.
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In conclusion, this study shows that though BP SCIT did 
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Additional supporting information may be found online in the Supporting Information section at the end of the article. 
